Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.

[1]  J. Shih,et al.  Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. , 2019, European journal of cancer.

[2]  J. Subramanian,et al.  Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib. , 2019, Seminars in oncology.

[3]  B. Han,et al.  Different characteristics and survival in non‐small cell lung cancer patients with primary and acquired EGFR T790M mutation , 2019, International journal of cancer.

[4]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Yu-An Dong,et al.  Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. , 2019, The oncologist.

[6]  L. Landi,et al.  Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations , 2019, Clinical lung cancer.

[7]  T. Jiang,et al.  Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. , 2019, Lung cancer.

[8]  M. Yomota,et al.  Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harbouring uncommon EGFR mutations: a case report and literature review , 2019, OncoTargets and therapy.

[9]  J. Ahn,et al.  OA10.05 An Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation(KCSG-LU15-09) , 2018, Journal of Thoracic Oncology.

[10]  S. Chuai,et al.  High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation. , 2018, Lung cancer.

[11]  D. Planchard,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Satomu Morita,et al.  Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations , 2018, Internal medicine.

[13]  Y. Shao,et al.  Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex. , 2018, Lung cancer.

[14]  N. Masuda,et al.  A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation , 2018, BMJ Case Reports.

[15]  S. Cascinu,et al.  Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. , 2018, Critical reviews in oncology/hematology.

[16]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[17]  Juan Zhou,et al.  Comparison of therapeutic effects of EGFR‐tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function , 2017, Thoracic cancer.

[18]  Yi-long Wu,et al.  A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. , 2017, Lung cancer.

[19]  Ying Cheng,et al.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[20]  B. Han,et al.  First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  F. Hirsch,et al.  Comprehensive Analysis of EGFR‐Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  Yi-long Wu,et al.  A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  T. Nakajima,et al.  Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR‐Mutant Non–small‐cell Lung Cancer , 2017, Clinical lung cancer.

[24]  Xiaozhen Liu,et al.  Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion‐positive non–small cell lung cancer , 2017, Cancer.

[25]  M. Tsao,et al.  Uncommon EGFR mutations in advanced non-small cell lung cancer. , 2017, Lung cancer.

[26]  Y. Yatabe,et al.  Association Between EGFR T790M Status and Progression Patterns During Initial EGFR‐TKI Treatment in Patients Harboring EGFR Mutation , 2017, Clinical lung cancer.

[27]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[28]  J. Shih,et al.  Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer , 2016, OncoTargets and therapy.

[29]  T. Mitsudomi,et al.  Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy , 2016, Cancer science.

[30]  Yusuke Nakamura,et al.  Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor? , 2016, Cancer science.

[31]  Y. Yatabe,et al.  Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  Kenichi Suda,et al.  EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs , 2015, Clinical Cancer Research.

[33]  L. Sequist,et al.  Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. , 2015, The Lancet. Oncology.

[34]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[35]  W. Pao,et al.  Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.

[36]  W. Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[37]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  I. Wistuba,et al.  Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. , 2013, Lung cancer.

[39]  Wendy Winckler,et al.  Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 , 2012, Proceedings of the National Academy of Sciences.

[40]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[41]  J. Shih,et al.  Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer , 2011, Clinical Cancer Research.

[42]  William Pao,et al.  Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation , 2010, Clinical Cancer Research.

[43]  A. Gemma,et al.  F1000 highlights , 2010 .

[44]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[45]  T. Mok,et al.  Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. , 2008, Cancer letters.

[46]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[47]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[48]  L. Paz-Ares,et al.  Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  Yang Zhang,et al.  Are exon 19 deletions and L858R different in early stage lung adenocarcinoma? , 2017, Journal of Cancer Research and Clinical Oncology.

[50]  J-L Pretet,et al.  Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  S. Kobayashi,et al.  EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. , 2012, The Lancet. Oncology.